for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Indivior PLC

INDV.L

Latest Trade

165.00GBp

Change

6.50(+4.10%)

Volume

3,759,750

Today's Range

157.90

 - 

168.60

52 Week Range

67.00

 - 

168.60

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
158.50
Open
158.40
Volume
3,759,750
3M AVG Volume
22.21
Today's High
168.60
Today's Low
157.90
52 Week High
168.60
52 Week Low
67.00
Shares Out (MIL)
734.84
Market Cap (MIL)
1,159.46
Forward P/E
16.98
Dividend (Yield %)
--

Next Event

Indivior PLC Annual Shareholders Meeting

Latest Developments

More

Indivior Reiterates Upgraded FY21 Outlook

Addex Therapeutics And Indivior Extend Research Collaboration On Gabab Positive Allosteric Modulators

Indivior Lifts FY 2021 Outlook

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.

Industry

Biotechnology & Drugs

Contact Info

103-105 Bath Road

SL1 3UH

United Kingdom

+44.1753.217800

http://indivior.com/

Executive Leadership

Graham Hetherington

Non-Executive Independent Chairman of the Board

Mark Crossley

Chief Executive Officer, Executive Director

Ryan Preblick

Chief Financial Officer, Executive Director

Jon Fogle

Chief Human Resource Officer

Christian Heidbreder

Chief Scientific Officer

Key Stats

1.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.0K

2019

0.8K

2020

0.6K

2021(E)

0.7K
EPS (USD)

2018

0.370

2019

0.230

2020

0.080

2021(E)

0.130
Price To Earnings (TTM)
18.70
Price To Sales (TTM)
2.40
Price To Book (MRQ)
9.84
Price To Cash Flow (TTM)
14.45
Total Debt To Equity (MRQ)
171.95
LT Debt To Equity (MRQ)
164.63
Return on Investment (TTM)
10.54
Return on Equity (TTM)
6.08

Latest News

Latest News

RPT-UPDATE 1-Indivior lifts outlook on strong sales of addiction treatments

Indivior Plc on Wednesday raised its annual revenue and profit forecast, encouraged by strong sales of its opioid addiction treatments in the first half of the year as patients resumed routine visits to clinics and hospitals, sending its shares 10.5% higher in early trade.

UPDATE 1-Indivior lifts outlook on strong sales of addiction treatments

Indivior Plc on Wednesday raised its annual revenue and profit forecast, encouraged by strong sales of its opioid addiction treatments in the first half of the year as patients resumed routine visits to clinics and hospitals, sending its shares 10.5% higher in early trade.

Indivior raises revenue forecast as U.S. opioid treatment sales recover

Indivior Plc revised its annual revenue forecast higher than earlier on Friday, encouraged by a recovery in U.S. sales of the British drugmaker's opioid addiction treatment in the fourth quarter, sending its shares up by 7.4% in early trade.

London stocks set for weekly loss; Indivior jumps

British shares dropped on Friday and were set to close the week lower as fresh lockdowns and rising virus cases dampened hopes of a swift economic recovery, while drugmaker Indivior gained on higher revenue forecast.

Indivior forecasts revenue above target as opioid treatment sales recover

British drugmaker Indivior Plc said it now expects annual revenue to be in the range of $645 to $650 million, higher than its prior forecast, thanks to recovery in sales of its opioid addiction treatment in the final quarter.

Ex-Indivior medical director sentenced to six months home detention

A former Indivior PLC executive was sentenced to six months' home detention on Thursday, after he pleaded guilty to a criminal charge arising out of a federal investigation into the marketing of the company's opioid addiction treatment Suboxone.

Indivior to 'vigorously defend' Reckitt Benckiser's $1.4 billion claim

British drugmaker Indivior Plc said on Monday it would "vigorously defend" against a 1.07 billion pound ($1.43 billion) legal claim from consumer good maker Reckitt Benckiser Group relating to their demerger agreement.

Drugmaker Indivior appoints Preblick as permanent finance chief

British drugmaker Indivior Plc said on Friday it has appointed interim Chief Financial Officer Ryan Preblick to the role permanently, taking over from Mark Crossley who became the company's CEO this year.

CORRECTED-Indivior quarterly profit slumps, sets full-year revenue target

British drugmaker Indivior Plc reported a near 70% slump in third-quarter profit on Thursday and said it expects full-year net revenue between a range of $595 million to $620 million.

UPDATE 1-Drugmaker Indivior's Q3 profit slumps, sets full-year revenue target

British drugmaker Indivior Plc reported a near 70% slump in third-quarter profit on Thursday and said it expects full-year net revenue between a range of $595 million and $620 million.

Indivior can't reverse Suboxone antitrust class certification

A federal appeals court on Tuesday ruled that purchasers of the opioid addiction treatment drug Suboxone could sue Indivior Plc as a class over allegations it engaged in an scheme to impede competition by generic versions of the product.

Indivior to pay $600 million to settle U.S. opioid treatment marketing claims

Indivior Plc has agreed to pay $600 million and have a subsidiary plead guilty to a felony charge to resolve U.S. allegations that it engaged in an illegal scheme to boost prescriptions of its opioid addiction treatment Suboxone.

BRIEF-Indivior Notes Ex-CEO Shaun Thaxter In Agreement With U.S. Dept Of Justice

* INDIVIOR PLC - NOTES THAT SHAUN THAXTER, ITS FORMER CHIEF EXECUTIVE OFFICER, ENTERED INTO AN AGREEMENT WITH U.S. DEPARTMENT OF JUSTICE

Former Indivior CEO pleads guilty in U.S. in opioid addiction treatment probe

Shaun Thaxter, the former chief executive of drugmaker Indivior Plc, pleaded guilty on Tuesday to a criminal charge arising out of a U.S. Justice Department investigation into the marketing of its opioid addiction treatment Suboxone.

Ex-CEO of opioid treatment maker Indivior pleads guilty in U.S.

Shaun Thaxter, the former chief executive of drugmaker Indivior Plc, pleaded guilty on Tuesday to a criminal charge arising out of a U.S. Justice Department investigation into the marketing of its opioid addiction treatment Suboxone.

BRIEF-Indivior Says 24-Month Outcomes Of Recover Study Presented

* INDIVIOR PLC - 24-MONTH OUTCOMES OF RECOVER STUDY PRESENTED Source text for Eikon: Further company coverage:

BRIEF-Indivior Says Chair Howard Pien To Take Leave Of Absence For Medical Reasons

* INDIVIOR PLC ANNOUNCES THAT CHAIR, HOWARD PIEN, IS TO TAKE A LEAVE OF ABSENCE FOR MEDICAL REASONS

BRIEF-Indivior Gets Nod For Subutex For Substitution Treatment Of Opioid Dependence In Sweden

* INDIVIOR RECEIVES APPROVAL FOR SUBUTEX® PROLONGED RELEASE SOLUTION FOR INJECTION, 100MG AND 300MG FOR SUBSTITUTION TREATMENT OF OPIOID DEPENDENCE IN SWEDEN Source text for Eikon: Further company coverage:

BRIEF-Indivior PLC Shifts AGM Venue

* INDIVIOR PLC - AGM WILL NO LONGER BE HELD AT ORIGINAL VENUE AND MEETING WILL NOW BE HELD AT COMPANY'S REGISTERED OFFICE

BRIEF-Indivior Says Safety Profile Of Up To 12-Month Sublocade Treatment Consistent With Transmucosal Buprenorphine

* INDIVIOR - SAFETY PROFILE OF UP TO 12-MONTH SUBLOCADE TREATMENT CONSISTENT WITH TRANSMUCOSAL BUPRENORPHINE, WITH ANTICIPATED INJECTION-SITE REACTIONS EXCEPTION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up